Literature DB >> 10212015

Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs.

C Chen1, E J Casale, B Duncan, E H Culverhouse, J Gilman.   

Abstract

We evaluated the pharmacokinetics of lamotrigine in 12 children with epilepsy who were receiving no other antiepileptic drugs. Each patient received a single oral dose of lamotrigine 2 mg/kg. Plasma concentrations of the drug were measured up to 48 hours after dosing. Pharmacokinetic parameters were calculated using noncompartmental methods. After rapid absorption, the lamotrigine concentration declined monoexponentially. Oral clearance was 0.64 +/- 0.26 ml/min/kg. The apparent volume of distribution was 1.50 +/- 0.51 L/kg. Weight-normalized clearance and volume were higher in children than in adults. The mean half-life was 32 hours, similar to that in adults. Should similar plasma lamotrigine concentrations in adults and children be desirable, children will likely require higher weight-normalized doses at the same dosing frequency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10212015     DOI: 10.1592/phco.19.6.437.31052

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  15 in total

Review 1.  Pharmacokinetic considerations in the treatment of childhood epilepsy.

Authors:  Jamie T Gilman; Michael Duchowny; Ana E Campo
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 2.  Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Authors:  Svein I Johannessen; Torbjörn Tomson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.

Authors:  Todd M Conner; Ronald C Reed; Tao Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

4.  Dynamic time course of typical childhood absence seizures: EEG, behavior, and functional magnetic resonance imaging.

Authors:  Xiaoxiao Bai; Matthew Vestal; Rachel Berman; Michiro Negishi; Marisa Spann; Clemente Vega; Matthew Desalvo; Edward J Novotny; Robert T Constable; Hal Blumenfeld
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

Review 5.  Lamotrigine. A review of its use in childhood epilepsy.

Authors:  C R Culy; K L Goa
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.022

Review 6.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Authors:  Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Use of second-generation antiepileptic drugs in the pediatric population.

Authors:  Allison M Chung; Lea S Eiland
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 8.  Pharmacokinetics and Drug Interaction of Antiepileptic Drugs in Children and Adolescents.

Authors:  Giulia Iapadre; Ganna Balagura; Luca Zagaroli; Pasquale Striano; Alberto Verrotti
Journal:  Paediatr Drugs       Date:  2018-10       Impact factor: 3.022

Review 9.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update.

Authors:  Domenico Italiano; Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

10.  Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach.

Authors:  Branka Brzaković; Katarina Vučićević; Sandra Vezmar Kovačević; Branislava Miljković; Milica Prostran; Žarko Martinović; Milena Pokrajac
Journal:  Eur J Clin Pharmacol       Date:  2013-11-19       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.